Log in
Enquire now
Argonaut Therapeutics

Argonaut Therapeutics

Precision therapeutics company developing epigenetic therapies that target arginine methylation in cancer.

OverviewStructured DataIssuesContributors
Is a
Organization
Organization
Company
Company
B2X
B2B
B2B
CEO
‌
Nick La Thangue
0
Company Operating Status
Active
Country
United Kingdom
United Kingdom
0
Crunchbase URL
crunchbase.com/organiz...apeutics
Date Incorporated
2016
Email Address
enquiries@argonauttherapeutics.co.uk
0
Facebook URL
@pages/Argonaut-Therapeutics-Ltd/900437230136046
Founded Date
2016
Founder
‌
Nick La Thangue
0
Full Address
Magdalen Centre 1 Robert Robinson Ave, Littlemore, Oxford OX4 4GA, United Kingdom
0
Industry
Regenerative medicine
Regenerative medicine
Therapeutics
Therapeutics
Gene therapy
Gene therapy
Drug development
Drug development
Epigenetics
Epigenetics
Oncology
Oncology
Therapy
Therapy
Cancer
Cancer
Biomedical engineering
Biomedical engineering
Biopharmaceutical
Biopharmaceutical
•••
Investors
OSI (Oxford Sciences Innovation)
OSI (Oxford Sciences Innovation)
Latest Funding Type
‌
Corporate funding round
LinkedIn URL
@company/argonaut-therapeutics-limited/about
Location
Oxford
Oxford
0
Number of Employees (Ranges)
11 – 50
Patents Assigned (Count)
1
Spun Out From
University of Oxford
University of Oxford
Total Funding Amount (USD)
2,600,000
Official Website
argonauttherapeutics.co.uk

Find more companies like Argonaut Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.